Drugs / 19(T2)28z1xx TRAC T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05757700 | Feb 2023 → Feb 2027 expected | high grade B-cell lymphoma, large B-cell lymphoma, primary mediastinal large B-cell lymphoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 19(T2)28z1xx TRAC T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05757700 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor (CAR) Modified T Cells” NCT05757700 ↗ |
| Target | CD19 | “CD19-Targeted” NCT05757700 ↗ |